Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Ltd (NQ: ARCT )

16.84 -0.14 (-0.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 489,806
Open 16.86
Bid (Size) 15.01 (1)
Ask (Size) 17.54 (1)
Prev. Close 16.98
Today's Range 16.31 - 17.94
52wk Range 12.12 - 65.00
Shares Outstanding 26,418,965
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022
Upgrades 
Via Benzinga
Expert Ratings for Arcturus Therapeutics
Within the last quarter, Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings: 
Via Benzinga

Performance

YTD
-57.44%
-57.44%
1 Month
-33.28%
-33.28%
3 Month
-27.57%
-27.57%
6 Month
-52.60%
-52.60%
1 Year
-41.43%
-41.43%

More News

Read More
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus' COVID-19 Vaccine Candidate Meets Primary Goal In Vietnam Study
Via Benzinga
Earnings Scheduled For February 28, 2022
Via Benzinga
Arcturus Therapeutics's Earnings Outlook
Via Benzinga
Arcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster Trial
Via Benzinga
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022
From Arcturus Therapeutics
Via Business Wire
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
28 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Dow Jumps 250 Points
Via Benzinga
The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus' COVID-19 Vaccine Trial Data, FDA Rejects Teva's Schizophrenia Med, Otonomy Aces Hearing Loss Study
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx
Via Benzinga
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Participate in the Barclays Global Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics's Earnings Outlook
Via Benzinga
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
From Arcturus Therapeutics
Via Business Wire
Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.